59 related articles for article (PubMed ID: 12796697)
1. Inverse relationship between Skp2 ubiquitin ligase and the cyclin dependent kinase inhibitor p27Kip1 in prostate cancer.
Ben-Izhak O; Lahav-Baratz S; Meretyk S; Ben-Eliezer S; Sabo E; Dirnfeld M; Cohen S; Ciechanover A
J Urol; 2003 Jul; 170(1):241-5. PubMed ID: 12796697
[TBL] [Abstract][Full Text] [Related]
2. Degradation of p57Kip2 mediated by SCFSkp2-dependent ubiquitylation.
Kamura T; Hara T; Kotoshiba S; Yada M; Ishida N; Imaki H; Hatakeyama S; Nakayama K; Nakayama KI
Proc Natl Acad Sci U S A; 2003 Sep; 100(18):10231-6. PubMed ID: 12925736
[TBL] [Abstract][Full Text] [Related]
3. Testing the importance of p27 degradation by the SCFskp2 pathway in murine models of lung and colon cancer.
Timmerbeul I; Garrett-Engele CM; Kossatz U; Chen X; Firpo E; Grünwald V; Kamino K; Wilkens L; Lehmann U; Buer J; Geffers R; Kubicka S; Manns MP; Porter PL; Roberts JM; Malek NP
Proc Natl Acad Sci U S A; 2006 Sep; 103(38):14009-14. PubMed ID: 16966613
[TBL] [Abstract][Full Text] [Related]
4. Over-expression of Skp2 is associated with resistance to preoperative doxorubicin-based chemotherapy in primary breast cancer.
Davidovich S; Ben-Izhak O; Shapira M; Futerman B; Hershko DD
Breast Cancer Res; 2008; 10(4):R63. PubMed ID: 18644126
[TBL] [Abstract][Full Text] [Related]
5. The role of homeostatic regulation between tumor suppressor DAB2IP and oncogenic Skp2 in prostate cancer growth.
Tsai YS; Lai CL; Lai CH; Chang KH; Wu K; Tseng SF; Fazli L; Gleave M; Xiao G; Gandee L; Sharifi N; Moro L; Tzai TS; Hsieh JT
Oncotarget; 2014 Aug; 5(15):6425-36. PubMed ID: 25115390
[TBL] [Abstract][Full Text] [Related]
6. Interaction of Nkx3.1 and p27kip1 in prostate tumor initiation.
Gary B; Azuero R; Mohanty GS; Bell WC; Eltoum IE; Abdulkadir SA
Am J Pathol; 2004 May; 164(5):1607-14. PubMed ID: 15111307
[TBL] [Abstract][Full Text] [Related]
7. SKP2 Knockout in Rb1/p53-Deficient Mouse Models of Osteosarcoma Induces Immune Infiltration and Drives a Transcriptional Program with a Favorable Prognosis.
Ferrena A; Wang J; Zhang R; Karadal-Ferrena B; Al-Hardan W; Singh S; Borjihan H; Schwartz EL; Zhao H; Oktay MH; Yang R; Geller DS; Hoang BH; Zheng D
Mol Cancer Ther; 2024 Feb; 23(2):223-234. PubMed ID: 37871911
[TBL] [Abstract][Full Text] [Related]
8. O-GlcNAcylation of E3 ubiquitin ligase SKP2 promotes hepatocellular carcinoma proliferation.
Feng Z; Yin J; Zhang Z; Chen Z; Huang L; Tang N; Wang K
Oncogene; 2024 Apr; 43(15):1149-1159. PubMed ID: 38396292
[TBL] [Abstract][Full Text] [Related]
9. Targeting the untargetable: RB1-deficient tumours are vulnerable to Skp2 ubiquitin ligase inhibition.
Gupta P; Zhao H; Hoang B; Schwartz EL
Br J Cancer; 2022 Oct; 127(6):969-975. PubMed ID: 35752713
[TBL] [Abstract][Full Text] [Related]
10. Combined intermittent fasting and ERK inhibition enhance the anti-tumor effects of chemotherapy via the GSK3β-SIRT7 axis.
Tang X; Li G; Shi L; Su F; Qian M; Liu Z; Meng Y; Sun S; Li J; Liu B
Nat Commun; 2021 Aug; 12(1):5058. PubMed ID: 34433808
[TBL] [Abstract][Full Text] [Related]
11. Skp2 and Slug Are Coexpressed in Aggressive Prostate Cancer and Inhibited by Neddylation Blockade.
Mickova A; Kharaishvili G; Kurfurstova D; Gachechiladze M; Kral M; Vacek O; Pokryvkova B; Mistrik M; Soucek K; Bouchal J
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799604
[TBL] [Abstract][Full Text] [Related]
12. The Skp2 Pathway: A Critical Target for Cancer Therapy.
Cai Z; Moten A; Peng D; Hsu CC; Pan BS; Manne R; Li HY; Lin HK
Semin Cancer Biol; 2020 Dec; 67(Pt 2):16-33. PubMed ID: 32014608
[TBL] [Abstract][Full Text] [Related]
13. Anti-cancer effect of danshen and dihydroisotanshinone I on prostate cancer: targeting the crosstalk between macrophages and cancer cells via inhibition of the STAT3/CCL2 signaling pathway.
Wu CY; Yang YH; Lin YY; Kuan FC; Lin YS; Lin WY; Tsai MY; Yang JJ; Cheng YC; Shu LH; Lu MC; Chen YJ; Lee KD; Kang HY
Oncotarget; 2017 Jun; 8(25):40246-40263. PubMed ID: 28157698
[TBL] [Abstract][Full Text] [Related]
14. Suppression of APC/CCdh1 has subtype specific biological effects in acute myeloid leukemia.
Ewerth D; Schmidts A; Hein M; Schnerch D; Kvainickas A; Greil C; Duyster J; Engelhardt M; Wäsch R
Oncotarget; 2016 Jul; 7(30):48220-48230. PubMed ID: 27374082
[TBL] [Abstract][Full Text] [Related]
15. Trial Watch: Proteasomal inhibitors for anticancer therapy.
Obrist F; Manic G; Kroemer G; Vitale I; Galluzzi L
Mol Cell Oncol; 2015; 2(2):e974463. PubMed ID: 27308423
[TBL] [Abstract][Full Text] [Related]
16. Caffeic acid phenethyl ester induced cell cycle arrest and growth inhibition in androgen-independent prostate cancer cells via regulation of Skp2, p53, p21Cip1 and p27Kip1.
Lin HP; Lin CY; Huo C; Hsiao PH; Su LC; Jiang SS; Chan TM; Chang CH; Chen LT; Kung HJ; Wang HD; Chuu CP
Oncotarget; 2015 Mar; 6(9):6684-707. PubMed ID: 25788262
[TBL] [Abstract][Full Text] [Related]
17. The Drosophila F-box protein dSkp2 regulates cell proliferation by targeting Dacapo for degradation.
Dui W; Wei B; He F; Lu W; Li C; Liang X; Ma J; Jiao R
Mol Biol Cell; 2013 Jun; 24(11):1676-87, S1-7. PubMed ID: 23552694
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical expression of Skp2 protein in oral nevi and melanoma.
Benevenuto-de-Andrade BA; León JE; Carlos R; Delgado-Azañero W; Mosqueda-Taylor A; Paes-de-Almeida O
Med Oral Patol Oral Cir Bucal; 2013 May; 18(3):e388-91. PubMed ID: 23385514
[TBL] [Abstract][Full Text] [Related]
19. Skp2 expression unfavorably impacts survival in resectable esophageal squamous cell carcinoma.
Liang Y; Hou X; Cui Q; Kang TB; Fu JH; Zhang LJ; Luo RZ; He JH; Zeng YX; Yang HX
J Transl Med; 2012 May; 10():73. PubMed ID: 22533738
[TBL] [Abstract][Full Text] [Related]
20. Novel roles of Skp2 E3 ligase in cellular senescence, cancer progression, and metastasis.
Wang G; Chan CH; Gao Y; Lin HK
Chin J Cancer; 2012 Apr; 31(4):169-77. PubMed ID: 22200179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
